Table of Contents
ISRN Vascular Medicine
Volume 2013, Article ID 168504, 7 pages
http://dx.doi.org/10.1155/2013/168504
Clinical Study

Lipid Lowering Therapy with Combination of Niacin and Statin in Women: Age-Related Endothelial Effects

1Department of Cardiology, Hartford Hospital, 80 Seymour Street, P.O. Box 5037, Hartford, CT 06102-5037, USA
2Women’s Heart Center, Cedars-Sinai Heart Institute, Los Angeles, CA 90048, USA

Received 3 September 2013; Accepted 10 November 2013

Academic Editors: P. Schoenhagen and M. Shechter

Copyright © 2013 Beth Parker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. A. Pearson, S. N. Blair, S. R. Daniels et al., “AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases,” Circulation, vol. 106, no. 3, pp. 388–391, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. I. Stensvold, A. Tverdal, P. Urdal, and S. Graff-Iversen, “Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women,” British Medical Journal, vol. 307, no. 6915, pp. 1318–1322, 1993. View at Google Scholar · View at Scopus
  3. M. H. Criqui, G. Heiss, R. Cohn et al., “Plasma triglyceride level and mortality from coronary heart disease,” The New England Journal of Medicine, vol. 328, no. 17, pp. 1220–1225, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. LaRosa, “Triglycerides and coronary risk in women and the elderly,” Archives of Internal Medicine, vol. 157, no. 9, pp. 961–968, 1997. View at Google Scholar · View at Scopus
  5. J. E. Hokanson and M. A. Austin, “Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies,” Journal of Cardiovascular Risk, vol. 3, no. 2, pp. 213–219, 1996. View at Google Scholar · View at Scopus
  6. T. R. Pedersen, A. G. Olsson, O. Færgeman et al., “Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S),” Circulation, vol. 97, no. 15, pp. 1453–1460, 1998. View at Google Scholar · View at Scopus
  7. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Mora, R. J. Glynn, J. Hsia, J. G. MacFadyen, J. Genest, and P. M. Ridker, “Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials,” Circulation, vol. 121, no. 9, pp. 1069–1077, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Mora, J. E. Buring, P. M. Ridker, and Y. Cui, “Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels a cohort study,” Annals of Internal Medicine, vol. 155, no. 11, pp. 742–750, 2011. View at Google Scholar · View at Scopus
  10. A. R. Sharrett, C. M. Ballantyne, S. A. Coady et al., “Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study,” Circulation, vol. 104, no. 10, pp. 1108–1113, 2001. View at Google Scholar · View at Scopus
  11. F. M. Sacks, P. Alaupovic, L. A. Moye et al., “VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial,” Circulation, vol. 102, no. 16, pp. 1886–1892, 2000. View at Google Scholar · View at Scopus
  12. Y. Cui, R. S. Blumenthal, J. A. Flaws et al., “Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality,” Archives of Internal Medicine, vol. 161, no. 11, pp. 1413–1419, 2001. View at Google Scholar · View at Scopus
  13. S. J. Robins, D. Collins, J. T. Wittes et al., “Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 12, pp. 1585–1591, 2001. View at Google Scholar · View at Scopus
  14. G. Brown, J. J. Albers, L. D. Fisher et al., “Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B,” The New England Journal of Medicine, vol. 323, no. 19, pp. 1289–1298, 1990. View at Google Scholar · View at Scopus
  15. B. G. Brown, X.-Q. Zhao, A. Chait et al., “Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease,” The New England Journal of Medicine, vol. 345, no. 22, pp. 1583–1592, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. W. E. Boden, J. L. Probstfield, T. Anderson et al., “Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy,” The New England Journal of Medicine, vol. 365, no. 24, pp. 2255–2267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. B. L. Abramson, P. Benlian, M. E. Hanson, J. Lin, A. Shah, and A. M. Tershakovec, “Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients,” Lipids in Health and Disease, vol. 10, article 146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. Lipid Research Clinics Program, The Manual of Laboratory Operations: Lipid and Lipoprotein Analysis, National Institutes of Health, Department of Health, Education and Welfare, Bethesda, Md, USA, 1974.
  19. M. Shechter, M. Sharir, M. J. Paul Labrador, J. Forrester, and C. N. Bairey Merz, “Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels < 100 mg/dl,” American Journal of Cardiology, vol. 86, no. 11, pp. 1256–1259, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Shechter, M. Sharir, M. J. P. Labrador et al., “Oral magnesium therapy improves endothelial function in patients with coronary artery disease,” Circulation, vol. 102, no. 19, pp. 2353–2358, 2000. View at Google Scholar · View at Scopus
  21. R. H. Selzer, H. N. Hodis, H. Kwong-Fu et al., “Evaluation of computerized edge tracking for quantifying intima-media thickness of the common carotid artery from B-mode ultrasound images,” Atherosclerosis, vol. 111, no. 1, pp. 1–11, 1994. View at Publisher · View at Google Scholar · View at Scopus
  22. J. H. Dwyer, P. Sun, H. Kwong-Fu, K. M. Dwyer, and R. H. Selzer, “Automated intima-media thickness: the Los Angeles atherosclerosis study,” Ultrasound in Medicine and Biology, vol. 24, no. 7, pp. 981–987, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. J. R. Guyton, A. C. Goldberg, R. A. Kreisberg, D. L. Sprecher, H. R. Superko, and C. M. O'Connor, “Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia,” American Journal of Cardiology, vol. 82, no. 6, pp. 737–743, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. A. J. Taylor, H. J. Lee, and L. E. Sullenberger, “The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3,” Current Medical Research and Opinion, vol. 22, no. 11, pp. 2243–2250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. J. L. Vacek, G. Dittmeier, T. Chiarelli, J. White, and H. H. Bell, “Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia,” American Journal of Cardiology, vol. 76, no. 3, pp. 182–184, 1995. View at Publisher · View at Google Scholar · View at Scopus
  26. J. M. Morgan, D. M. Capuzzi, and J. R. Guyton, “A new extended-release niacin (niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients,” American Journal of Cardiology, vol. 82, no. 12, pp. 29U–34U, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. R. F. Furchgott, “The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide,” Journal of the American Medical Association, vol. 276, no. 14, pp. 1186–1188, 1996. View at Publisher · View at Google Scholar · View at Scopus
  28. P. D. Cherry, R. F. Furchgott, J. V. Zawadzki, and D. Jothianandan, “Role of endothelial cells in relaxation of isolated arteries by bradykinin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 6, pp. 2106–2110, 1982. View at Google Scholar · View at Scopus
  29. J. Gutierrez, G. Ramirez, T. Rundek et al., “Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis statin therapy to prevent recurrent CV events,” Archives of Internal Medicine, vol. 172, pp. 909–919, 2012. View at Google Scholar
  30. F. E. Kuhn, E. R. Mohler, L. F. Satler, K. Reagan, D. Y. Lu, and C. E. Rackley, “Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity,” American Journal of Cardiology, vol. 68, no. 15, pp. 1425–1430, 1991. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Laclaustra, A. F. Frangi, A. G. Frangi, J. A. Casasnovas, and P. Cia, “Association of endothelial function and vascular data with LDL-c and HDL-c in a homogeneous population of middle-aged, healthy military men: evidence for a critical role of optimal lipid levels,” International Journal of Cardiology, vol. 125, no. 3, pp. 376–382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. T. Kuvin, M. E. Rämet, A. R. Patel, N. G. Pandian, M. E. Mendelsohn, and R. H. Karas, “A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression,” American Heart Journal, vol. 144, no. 1, pp. 165–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. S. A. Sorrentino, C. Besler, L. Rohrer et al., “Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy,” Circulation, vol. 121, no. 1, pp. 110–122, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Hermann, F. Enseleit, L. E. Spieker et al., “Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia,” Thrombosis Research, vol. 123, no. 3, pp. 460–465, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. G. O'Driscoll, D. Green, and R. R. Taylor, “Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month,” Circulation, vol. 95, no. 5, pp. 1126–1131, 1997. View at Google Scholar · View at Scopus